dona

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of dona

What is Dona?

Dona is a pharmacological agent containing crystalline glucosamine sulfate as its active ingredient. It belongs to the class of other non-steroidal anti-inflammatory and anti-rheumatic agents. Glucosamine is an endogenous substance, a normal constituent of the polysaccharide chains of cartilage matrix and synovial fluid glucosaminoglycans.

Mechanism and Composition

The active substance, glucosamine sulfate, is a naturally occurring amino sugar. In the body, it serves as a biological building block for the synthesis of various macromolecules, including:

  • Glycosaminoglycans
  • Proteoglycans
  • Hyaluronic acid

These components are essential for the structural integrity of articular cartilage and the viscosity of the fluid found in the joints.

Intended Use

Dona is primarily used for the management of symptoms associated with osteoarthritis. It is designed to address the underlying physiological requirements of joint tissues. In patients with osteoarthritic changes, the exogenous administration of glucosamine sulfate is intended to supplement the body's natural levels of this amino sugar.

Characteristics

The crystalline formulation of glucosamine sulfate in Dona is stabilized to ensure consistent delivery of the active component. Unlike standard analgesic treatments that focus solely on immediate pain relief, this agent is categorized as a symptomatic slow-acting drug in osteoarthritis. This means the onset of its effects is typically gradual, observed over a period of several weeks.

What side effects are possible with dona?

Possible side effects and safety information

The safety profile of crystalline glucosamine sulfate is formally classified in regulatory documents based on the likelihood and nature of adverse reactions. These effects are grouped by their frequency and the system-organ class affected, with the most commonly reported reactions involving the gastrointestinal and nervous systems.


Frequency Classification and System Affected

Adverse reactions classified as Common (may affect up to 1 in 10 people) typically include Gastrointestinal Disorders such as nausea, abdominal pain, flatulence, constipation, or diarrhea. Common effects on the Nervous System include headache and somnolence (drowsiness), along with general tiredness.

Uncommon reactions (may affect up to 1 in 100 people) are primarily associated with Skin and Subcutaneous Tissue Disorders, including erythema (skin redness), pruritus (itching), and rash. Other effects are listed under Unknown Frequency in official labels.


Documented Serious Safety Considerations

Regulatory documentation highlights specific high-level safety concerns. The product is contraindicated for individuals with a known shellfish allergy, as the active substance is typically derived from shellfish. Use is also contraindicated during pregnancy, lactation, and in children and adolescents under 18 years of age due to insufficient data.

Caution is advised for patients with Impaired Glucose Tolerance or Diabetes Mellitus, as increases in blood glucose have been reported, necessitating closer observation. For patients receiving oral Vitamin K antagonists (e.g., Warfarin), an increased anticoagulant effect has been documented, which may require monitoring of coagulation parameters (INR) as a high-level safety measure. The label also notes that exacerbation of asthma symptoms has been reported, sometimes following the initiation of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Documented Manifestations of Overdose

Overdose with crystalline glucosamine sulfate is generally associated with a low acute toxicity profile, as stated in government regulatory documentation. The documented clinical manifestations primarily involve symptoms affecting the gastrointestinal tract and the central nervous system. These documented signs may include headache, dizziness, nausea, vomiting, diarrhea, or constipation. Regulatory authorities indicate that severe or life-threatening organ toxicity resulting from an overdose of this specific compound is unlikely, even when ingesting doses significantly above the recommended therapeutic intake, supporting the low-risk classification.

Mandated Emergency Action

If an overdose is suspected, the official regulatory guidance mandates specific immediate steps. Treatment with the substance must be discontinued immediately. Authorities emphasize that the affected person should seek medical advice at once and contact a poison control center or emergency room for assessment. The official management protocol specifies that since no specific antidote is known, the required treatment must be symptomatic and supportive, focusing on managing the clinical symptoms that may present. The resulting official overdose profile is defined by non-severe clinical manifestations and non-specific, supportive management strategies.

Therapeutic Uses of dona

Quick Facts: Uses of Dona

  • Targeted Condition: Osteoarthritis of the knee.
  • Primary Benefit: Symptomatic relief from pain and discomfort related to the condition.
  • Goal of Use: To assist in the management of symptoms associated with mild to moderate joint deterioration.

Dona (crystalline glucosamine sulfate) is utilized for the management of symptoms associated with mild to moderate osteoarthritis of the knee. This therapeutic option is utilized for individuals experiencing joint discomfort, stiffness, and restricted movement due to degenerative joint changes.

Consistent use of this formulation may support an improved sense of joint mobility and assist in providing relief from symptoms such as pain. Symptomatic relief may not be observed immediately upon starting use, as the effects are generally gradual, becoming more apparent after several weeks of continuous application. The ultimate goal of this treatment is to provide relief from the discomfort that influences the physical function of the joint.

This medication is indicated for the management of these specific symptoms.

Eligibility and Restrictions for Use

This section outlines the official population eligibility and non-eligibility for Dona (crystalline glucosamine sulfate), based strictly on regulatory documents such as the Summary of Product Characteristics (SmPC). No therapeutic benefits, dosing, or safety narrative unrelated to eligibility are included.


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults (18 years and older) are the approved population [SmPC].
Populations for whom use is not recommended Children and adolescents under 18 years of age. Pregnant and lactating women [SmPC].
Populations for whom use is contraindicated Patients with known hypersensitivity to the active substance or excipients [SmPC]. Individuals with an allergy to shellfish [SmPC]. Patients with phenylketonuria (PKU) (for the powder form only) [SmPC].
Age-related eligibility rules Use in those below 18 years is not recommended as safety and efficacy are not established [SmPC]. Dosage adjustment is not required in otherwise healthy elderly patients [SmPC].
Condition-specific eligibility rules Patients with impaired glucose tolerance (diabetes) require closer monitoring of blood sugar levels [SmPC]. Patients with asthma or those on a controlled sodium diet should use with caution [SmPC].
Pregnancy and lactation eligibility status Not recommended during pregnancy or lactation due to insufficient data [SmPC].

Eligibility Classifications

Category Classification
Eligibility severity classification Contraindicated (absolute prohibition); Not Recommended (insufficient data/not established); Caution/Conditional Use (requires monitoring) [SmPC].

Resulting Eligibility Structure

Official eligibility statements:

  • The medicine is contraindicated in patients with known hypersensitivity, including shellfish allergy.
  • Use is not recommended in children and adolescents under 18 years as efficacy and safety are not established.
  • Use is not recommended during pregnancy or lactation due to insufficient data.
  • Patients with impaired glucose tolerance (diabetes) require close monitoring.
  • The powder form is contraindicated in patients with phenylketonuria.

Connection to the Overall Eligibility Profile

Regulatory documents establish the adult population (18 years and older) as the eligible user group. The profile defines clear absolute contraindications based on allergy and certain metabolic/excipient restrictions. Furthermore, it formally classifies use in pediatric, pregnant, and lactating populations as not recommended due to a lack of established efficacy and safety data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Glucosamine sulfate, the active substance in Dona, has a low potential for general drug interactions based on its physico-chemical and pharmacokinetic properties, including a lack of inhibition on major human cytochrome P450 enzymes (CYP1A2, CYP2C9, CYP3A4, etc.). However, official regulatory documents list two main categories of interacting products requiring specific action.

Oral Vitamin K Antagonists

The most clinically significant documented interaction is with Oral Vitamin K Antagonists (OVKAs), such as warfarin, dicoumarol, acenocoumarol, phenprocoumon, and fluidione. Reports have indicated a potential for the effect of these anticoagulants to be stronger, leading to an increase in the International Normalized Ratio (INR). This interaction may increase the risk of bleeding events.

Patients taking OVKAs must be closely monitored, and their coagulation parameters (INR) must be checked at the time of initiating and terminating glucosamine sulfate treatment.

Other Documented Interactions

  • Tetracyclines: Glucosamine sulfate may potentially enhance the gastrointestinal absorption of tetracyclines, though the clinical relevance is often considered limited.
  • Analgesics and NSAIDs: These products are often used concomitantly and are not listed as having a documented interaction requiring modification.
  • Metabolic Constraints: For patients with diabetes or impaired glucose tolerance, close monitoring of blood sugar levels and, if necessary, insulin requirements is recommended when starting treatment. Patients with asthma should also be monitored, as a worsening of symptoms has been reported in a few cases.

Mechanism of Action

Anabolic Support for Cartilage Structure

Glucosamine Sulfate Crystalline functions as a metabolic precursor, providing essential amino sugars that are integrated into the Hexosamine Biosynthesis Pathway (HBP). This action directly stimulates chondrocytes (cartilage cells) to increase the synthesis of structural components, including proteoglycans and collagen Type II. The mechanism's physiological effect is to contribute to the synthesis of structural components for the articular cartilage matrix, thereby facilitating the formation of the cartilage matrix.


Anti-Catabolic Enzyme Modulation

The specific sulfate salt acts as an inhibitor of the central transcription factor NF-κB within joint tissues. By blocking the activation of this factor, the drug downregulates the gene expression of key destructive enzymes, notably Matrix Metalloproteinases (MMPs) and ADAMTS-5 (Aggrecanase). This anti-catabolic mechanism limits the activity of enzymes involved in extracellular matrix degradation and modulates the expression of specific pro-inflammatory mediators, resulting in a net shift of the cellular balance toward anabolism.

Dosage and Administration Information

How Dona is Used in Clinical Practice

The usage of Dona (crystalline glucosamine sulfate 1500 mg) follows a standardized regimen, ensuring consistent oral administration.

Official Dosing and Administration

The route of administration is oral, with the standard adult regimen set at a fixed daily dose of 1500 mg crystalline glucosamine sulfate. This dose is typically delivered either as a powder for oral solution or as two 750 mg film-coated tablets taken together. The powder preparation requires the contents of one sachet to be fully dissolved in a glass of water before ingestion. Tablets should be swallowed whole with liquid.

Contextual Usage Principles

The medication is to be taken once daily, and administration is generally recommended to occur with meals. This medicine is not intended for the treatment of acute, sudden pain. Because the therapeutic effects are slow and cumulative, a prescribed course of administration is designed to be assessed over time. If the patient does not experience relief of symptoms after 2 to 3 months of continuous, daily use, a re-evaluation of treatment continuation is required.

Population-Specific Rules

Use of the product is not recommended in children and adolescents under 18 years of age due to insufficient data supporting its safety and efficacy in this population. For otherwise healthy older adults, no adjustment to the standard 1500 mg dose is specified. Due to the presence of approximately 151–155 mg of sodium per daily dose, the composition must be considered for individuals maintaining a controlled sodium diet.

Recent Clinical Evidence

dona: Recent Clinical Evidence

Research for conditions characterized by fluctuating manifestations

Research for dona was studied for conditions characterized by fluctuating or episodic manifestations. The types of research applied in studies examining patient-reported experiences include both smaller-scale research and larger trials used in research exploring how symptoms change over time. These studies include research evaluating outcomes related to physical discomfort and outcomes describing episodic or acute changes.

Data show patterns related to how symptoms evolved in the observed populations. This information contributes to the broader evidence landscape by showing what has been observed in these settings. However, data are still emerging for this area of use. Most of the studies conducted were research exploring short-term symptom changes, meaning follow-up durations were limited. This means long-term effects are not fully established, and certainty remains low regarding whether the patterns observed continue beyond the brief study window.

Research for conditions marked by functional limitations

Dona was evaluated in studies focusing on conditions marked by functional limitations, particularly in observational settings evaluating daily-life functioning. This research examined outcomes related to systemic or functional imbalance and patient-reported outcomes describing perceived discomfort. The research was conducted during periods of increased symptom activity and studies monitored responses over defined time intervals, with a focus on chronic, ongoing challenges.

The data show patterns related to how participants reported their outcomes reflecting daily functioning or activity level. Specifically, some studies observed patterns related to changes in how people managed certain daily tasks. For this indication, the findings were mixed across different research settings. The evidence quality varies across studies, and comparative evidence is lacking. Research is ongoing to clarify the role of dona in managing these conditions presenting with cycles of stability and flare-ups.

Understanding the Evidence: Limitations and Gaps

Studies help show what has been observed so far, but this research provides context but not individual predictions. The findings describe group patterns, not personal outcomes. For any individual, the research provides context, but does not predict whether an individual will respond similarly to the average patterns seen in the studies. As with most medical research, long-term effects are not fully established.

Frequently Asked Questions (FAQ)

Common questions about dona (FAQ)


Q: Is dona considered a pain reliever or something else?

Official product information describes dona as a Structure-Modifying Osteoarthritis Drug (SYSADOA). It is not indicated for the relief of acute or sudden painful symptoms. Its effects are slow and work gradually over several weeks, differentiating it from rapid pain relief medications.


Q: What is the recommended duration of treatment with dona?

In clinical studies, the safety and patterns of effectiveness have been confirmed for treatment durations up to three years. If a person does not experience symptom relief after 2 to 3 months of continuous, daily use, regulatory documents recommend re-evaluating the continuation of treatment.


Q: Is there official information available about using dona long-term?

While clinical trials have confirmed efficacy for up to three years, regulatory documents indicate that continuous treatment beyond a 3-year period has not been evaluated for safety. This is a limit based on the established safety and efficacy data from the clinical trials.


Q: Does the form of dona (tablet vs. powder) change how it works?

Official documents indicate that both the film-coated tablets and the powder for oral solution contain the same daily 1500 mg dose of crystalline glucosamine sulfate. Regulatory information does not describe any difference in the fundamental way the medication works (its mechanism of action) or its overall efficacy based on the form taken.


Q: Is it true that official sources recommend taking dona for a minimum of 6 weeks?

The official product information specifies a longer assessment period. It recommends re-evaluating treatment continuation if no relief of symptoms is experienced after 2 to 3 months (or 8–12 weeks) of continuous daily use, not 6 weeks.


Q: Why do some people use dona for general joint wellness, not just specific conditions?

Official regulatory texts describe the product’s use for the relief of symptoms in mild to moderate osteoarthritis, but do not contain information regarding its use for general joint wellness. Its primary purpose, according to the label, is to support the joint cartilage.


Q: What are the signs of a serious, but rare, side effect from dona?

Serious but rare adverse reactions, primarily allergic reactions, may occur. According to official documents, signs of a serious allergic reaction, such as swelling of the face, lips, tongue, or throat, or difficulty breathing, are recognized as requiring prompt consultation with a healthcare professional.


Q: Does the drug's purpose relate only to the joints, or other parts of the body?

The action of dona is targeted toward the joints. Its mechanism is focused on supporting the synthesis of components in the cartilage matrix and synovial fluid (the joint's lubricating fluid).


Q: Can dona be used by people who follow a vegetarian diet?

The active ingredient, glucosamine sulfate, is typically sourced naturally from the shells of shellfish (such as crabs and shrimp). The fact that it is sourced from shellfish may be a relevant consideration for individuals following vegetarian or vegan diets.


Q: What should I do if I miss a scheduled dose of dona?

Official patient advice states that if you realize you missed a dose and it is almost time for the next scheduled dose, the missed dose should be skipped. Otherwise, the dose should be taken as soon as you remember. A double dose must not be taken to compensate for a forgotten one.


Q: Is it common for the effects of dona to wear off after stopping the medication?

Clinical studies described in regulatory documents have demonstrated a residual effect for up to two months after the medicine is withdrawn. This information indicates that the positive effects may persist for some time after stopping the product.


Q: Is dona safe for people with high blood pressure?

Available literature suggests that individuals with existing high blood pressure (hypertension) may require close monitoring of their blood pressure. While some early data suggested a possible link to blood pressure, more authoritative research generally indicates that glucosamine sulfate does not typically affect blood pressure.


Q: Are there specific food or drink items to avoid while taking dona?

Specific foods are not listed for mandatory avoidance in the official product information. However, caution is required for individuals on a controlled sodium diet, as the product has a measurable sodium content that must be considered.


Q: Can people who are lactose intolerant safely take dona?

The tablet formulation of dona contains lactose. Official safety information indicates that patients with rare hereditary problems such as total lactase deficiency or galactose intolerance are advised against taking the tablet form of this medicine.


Q: Is dona a prescription-only medicine in all countries?

The regulatory status of the product varies globally. It is sold as a prescription-only medicine in certain regions (such as many countries in Europe) but is available without a prescription in other regions.


Q: What does 'use conditions' mean when doctors talk about dona?

When discussing a medicine, use conditions refer to the specific medical situations for which the drug has been officially studied and approved by regulatory bodies. For dona, this is the relief of symptoms in mild to moderate osteoarthritis of the knee.


Q: Are there any research studies examining the use of dona in athletes?

Regulatory-adjacent research has examined the potential role of glucosamine in the primary prevention of osteoarthritis in sportsmen and athletes. This research is noted in scientific literature but is not the primary focus of the drug's official regulatory indication.


Q: Can people with liver issues use dona?

Official documents state that no specific dosing recommendations are available for patients with impaired liver (hepatic) or kidney (renal) function, as dedicated studies have not been performed. Individuals with severe hepatic or renal insufficiency should use the medication only under medical supervision.


Q: What does it mean if dona is described as an 'adjunct therapy'?

While the term 'adjunct therapy' is not used in the official product documents, the drug class to which dona belongs is often described as an important background therapy for people with knee osteoarthritis. This means it is typically used in addition to other treatments or lifestyle modifications.


Q: Does official guidance list any known interactions with alcohol?

The liquid or powder forms of this product may contain excipient alcohol. Individuals with liver disease or any medical condition requiring them to limit or strictly avoid alcohol should consider this factor.


Q: Is there a difference in effectiveness between the brand-name dona and generics?

Studies cited in authoritative reviews indicate that the efficacy of glucosamine can be dependent on the specific formulation being studied. Research often suggests that the specific crystalline formulation used in the Dona brand was found to offer better outcomes regarding pain and function compared to certain generic or non-specific preparations.


Q: Can dona be taken alongside other common chronic disease medications?

Based on its chemical properties, the product is understood to have a low potential for interactions with most common drugs. The main exceptions listed in regulatory documents involve Oral Vitamin K Antagonists (like warfarin) and Tetracycline-class antibiotics.


Q: What does the term 'chondroprotective' mean in relation to dona?

This term, often used in scientific literature, refers to agents that offer protection to the articular cartilage and other joint tissues. This is related to the drug's function, which is described as having anabolic (building) and anti-catabolic (anti-degrading) effects on the cartilage matrix.


Q: Is there any research on how quickly dona is eliminated from the body?

Official product information includes pharmacokinetic data on how the substance is processed by the body. Following administration, glucosamine is reported to have a biological half-life of about 70 hours, indicating how quickly half of the drug is eliminated.


Q: Is there a maximum time frame for continuous use of dona described in official leaflets?

Official regulatory documents state that continuous treatment beyond three years cannot be formally recommended. This is a limit based on the established safety and efficacy data from the conducted clinical trials.


Q: Does taking a double dose accidentally increase the risk of side effects?

Official patient information explicitly states that a double dose must not be taken to compensate for a missed one. Taking too much may lead to discomfort or signs of poisoning, and medical consultation is required in the event of an overdose.


Q: Is it necessary to inform other doctors that I am taking dona?

Official guidance emphasizes the importance of informing all healthcare practitioners, doctors, and pharmacists that the patient is taking this product. This is particularly relevant when starting, stopping, or changing the dose of any other medicine.


Q: Does dona have a specific contraindication for people with kidney disease?

Official product information notes that no specific dosing guidance is available for people with impaired kidney (renal) function due to a lack of dedicated studies. However, administration to patients with severe hepatic or renal insufficiency should occur under medical supervision.

How should dona be stored and disposed of?

How to Store and Dispose of Dona Glucosamine Sulfate

Storage Requirements

Dona must be stored according to specific regulatory conditions to maintain its stability. The capsule formulation must be kept below 30 °C (eighty-six degrees Fahrenheit), and the powder for oral solution must be stored below 25 °C. It is prohibited to store the medicine in environments prone to heat and dampness, such as in the bathroom, near a sink, or on window sills. The product must be stored in its original, intact packaging and must not be used after the expiry date.

Child Safety and Disposal

For child protection, Dona must be kept out of the sight and reach of children. Official guidance recommends returning any unused or expired product to a pharmacist for proper disposal. The medicine must not be thrown away via wastewater or household waste, as these environmental measures are mandated by regulatory agencies.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of dona found in:

A-Z Index: